Clinical Trials Browser

Neoplasm, Residual × Immunotherapy × Thoracic × Clear all

NCT05460195 2022-07-15

Sintilimab Combined With Anlotinib for Perioperative Non-small Cell Lung Cancer Based on MRD Evaluation

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung, Neoplasm, Residual